Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib maintenance in relapsed ovarian cancer
NCT00710762Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2006
- Primary completion
- Sep 2008
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing Nintedanib with Placebo (2 arms). Primary endpoint: Progression-Free Survival Rate at 36 Weeks. Started Mar 2006; status: completed.
02
Drugs
nintedanib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00710762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00710762.